-
1
Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
Published 2025-01-01Subjects: “…Afatinib…”
Get full text
Article -
2
Dermatologic Adverse Events Following Afatinib in a Woman with Non-Small-Cell Lung Cancer: A Case Report
Published 2025-01-01Subjects: “…afatinib…”
Get full text
Article -
3
Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Ad...
Published 2024-01-01Subjects: “…afatinib…”
Get full text
Article